Sisram MedicalSRAMF 60 3-Year ROIIC % is -22.71 as of Dec. 2025. GuruFocus rates SRAMF with a GF Score™ of 60/100 and a GF Value™ of $0.90 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 799 Medical Devices & Instruments companies, Sisram Medical ranks worse than 70.59% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Sisram Medical's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was -22.71%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Sisram Medical's 3-Year ROIIC % or its related term are showing as below:
SRAMF's 3-Year ROIIC % is ranked worse than 70.59% of 799
companies
in the Medical Devices & Instruments industry
Industry Median: 1.67
vs SRAMF: -22.71
Sisram Medical (OTCPK:SRAMF) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Sisram Medical 3-Year ROIIC % Related Terms
Sisram Medical 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Sisram Medical's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Sisram Medical's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sisram Medical 3-Year ROIIC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sisram Medical's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Sisram Medical's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Sisram Medical (SRAMF) has a 3-Year ROIIC % of -22.71 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Sisram Medical and its competitors. According to the industry distribution chart, Sisram Medical ranks #564 out of 799 companies in the Medical Devices & Instruments industry, placing it in the top 70.6%.
Is Sisram Medical's 3-Year ROIIC % too high?
Sisram Medical's current 3-Year ROIIC % is -22.71. Based on the distribution chart, Sisram Medical ranks #564 out of 799 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Sisram Medical has a GF Score™ of 60/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sisram Medical's 3-Year ROIIC % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Sisram Medical ranks #564 out of 799 companies for 3-Year ROIIC %. This places Sisram Medical in the lower half of its industry. The industry median 3-Year ROIIC % is 1.67. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Devices & Instruments company?
The median 3-Year ROIIC % among Medical Devices & Instruments companies is 1.67, based on 799 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Sisram Medical and its competitors. For the Medical Devices & Instruments industry, the median 3-Year ROIIC % is 1.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sisram Medical's current 3-Year ROIIC % is -22.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sisram Medical stock overvalued right now?
Based on GuruFocus' analysis, Sisram Medical (SRAMF) is currently considered Significantly Undervalued. The stock's GF Value™ is $0.90, compared to a current price of $0.44 — trading 51.3% below its estimated fair value. The current 3-Year ROIIC % is -22.71. Sisram Medical's overall GF Score™ is 60/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Sisram Medical (SRAMF), the current 3-Year ROIIC % is -22.71 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sisram Medical (SRAMF) Overvalued in 2026?
Based on GuruFocus' analysis, Sisram Medical stock appears to be undervalued.
The current stock price of $0.44 is trading 51.3% below its estimated GF Value™ of $0.90.
GuruFocus considers Sisram Medical to be Significantly Undervalued.
Key valuation signals for SRAMF:
3-Year ROIIC %: -22.71
GF Value™: $0.90 vs. price of $0.44 (51.3% below fair value)
No single metric tells the full story. See the SRAMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sisram Medical Ltd is an investment holding company specializing in medical technology for healthcare. The Company is involved in research, development, design, manufacture, sale and marketing of medical aesthetics and dental equipment, home use devices, injectables and cosmeceuticals products. The company's products include Soprano Titanium, Colibri technology, and others. Some of the company's brands are Alma, Soprano, Copulla, and LMNT. It operates through the following geographical segments: North America which is its key revenue generating market, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
60GF Score
Get the complete analysis for SRAMF
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SRAMF has been successfully added to your 
